Similar results were replicated by Gilbert et al. [195] and Casellini et al. [196], showing reduced urinary levels of TGF-β, suggesting truncation of renal fibrosis and diabetic nephropathy; these findings indeed demonstrated the promising potential of PKC inhibitors to be used to protect against diabetes-derived microvascular complications. This evidence concerns the gene TGFB1 and diabetic kidney disease.